Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Claudin6 + GPC3 + Mesothelin + AXL
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
This is an investigational cell therapy product consisting of natural killer (NK) cells engineered with chimeric antigen receptors (CARs) targeting four tumor-associated antigens: Claudin6, Glypican 3 (GPC3), Mesothelin, and AXL. The therapy is designed to recognize and kill cancer cells expressing any of these antigens. The CAR-NK cells are generated by isolating NK cells from the patient, transfecting them with CAR constructs specific for one or more of the target antigens, expanding them ex vivo, and then infusing them back into the patient. Some versions may include additional genetic modifications to enhance anti-tumor activity or resistance to immunosuppression. This approach aims to treat advanced solid tumors that express at least one of these targets, such as ovarian cancer and other solid malignancies[1][3][6].
- Other names
- CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy
02
Targets
CLDN6 (Claudin-6)GPC3 (Glypican-3)AXL (AXL receptor tyrosine kinase)Mesothelin
Beyond the preview
Go deeper on Claudin6 + GPC3 + Mesothelin + AXL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin6 + GPC3 + Mesothelin + AXL.